187 related articles for article (PubMed ID: 8630516)
1. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours.
Salvatore D; Celetti A; Fabien N; Paulin C; Martelli ML; Battaglia C; Califano D; Monaco C; Viglietto G; Santoro M; Fusco A
Eur J Endocrinol; 1996 Feb; 134(2):177-83. PubMed ID: 8630516
[TBL] [Abstract][Full Text] [Related]
2. G --> A mutation of ras genes and infrequent p53 gene mutation in rat transplantable thyroid carcinoma lines from tumors induced in vivo by N-bis(2-hydroxypropyl)nitrosamine.
Kitahori Y; Naitoh H; Konishi N; Fukushima M; Ohnishi T; Hiasa Y
Cancer Lett; 1996 Feb; 100(1-2):55-62. PubMed ID: 8620454
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
4. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumours without radiation history.
Smida J; Zitzelsberger H; Kellerer AM; Lehmann L; Minkus G; Negele T; Spelsberg F; Hieber L; Demidchik EP; Lengfelder E; Bauchinger M
Int J Cancer; 1997 Dec; 73(6):802-7. PubMed ID: 9399655
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
7. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
8. Sporadic p53 mutations and absence of ras mutations in glioblastomas.
Gömöri E; Dóczi T; Pajor L; Matolcsy A
Acta Neurochir (Wien); 1999; 141(6):593-9. PubMed ID: 10929724
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.
Nakamura T; Yana I; Kobayashi T; Shin E; Karakawa K; Fujita S; Miya A; Mori T; Nishisho I; Takai S
Jpn J Cancer Res; 1992 Dec; 83(12):1293-8. PubMed ID: 1483945
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
[TBL] [Abstract][Full Text] [Related]
11. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas.
Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G
Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509
[TBL] [Abstract][Full Text] [Related]
12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
13. Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours.
Suchy B; Waldmann V; Klugbauer S; Rabes HM
Br J Cancer; 1998 Mar; 77(6):952-5. PubMed ID: 9528840
[TBL] [Abstract][Full Text] [Related]
14. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Shi Y; Zou M; Farid NR; al-Sedairy ST
Br J Cancer; 1996 Nov; 74(9):1336-41. PubMed ID: 8912526
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations in thyroid tumor progression: association with p53 gene mutations.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Jpn J Cancer Res; 1993 May; 84(5):526-31. PubMed ID: 8100564
[TBL] [Abstract][Full Text] [Related]
16. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations in all stages of thyroid carcinomas.
Zou M; Shi Y; Farid NR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
[TBL] [Abstract][Full Text] [Related]
18. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
19. FHIT gene abnormalities in both benign and malignant thyroid tumours.
Zou M; Shi Y; Farid NR; al-Sedairy ST; Paterson MC
Eur J Cancer; 1999 Mar; 35(3):467-72. PubMed ID: 10448301
[TBL] [Abstract][Full Text] [Related]
20. Oncogene profile of papillary thyroid carcinoma.
Sugg SL; Ezzat S; Zheng L; Freeman JL; Rosen IB; Asa SL
Surgery; 1999 Jan; 125(1):46-52. PubMed ID: 9889797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]